Barron’s Weekend Stock Picks: Verizon, VF Corp And Altria’s Dividend Yield

Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read.

Benzinga reviews this weekend’s top stories covered by Barron’s. Here are the articles investors need to read.

In “Verizon Stock Is Having Its Best Week Since January. Here’s What Sparked the Rally,” Angela Palumbo writes that Verizon Communication Inc‘s (NYSE:VZ) stock had its best week since January after reporting strong Q3 earnings and a higher dividend yield, despite a slight drop on Friday.

In “Dexcom Stock Soars on Earnings. Ozempic Isn’t the Threat It Was Supposed to Be,” Jacob Sonenshine explains that DexCom, Inc‘s (NASDAQ:DXCM) stock is rising as strong earnings suggest that the adoption of diabetes drugs like Ozempic isn’t significantly impacting the demand for continuous glucose monitoring devices, with sales and profit margins exceeding expectations.

In “VF Corp Activist Sees Stock Doubling,” Carleton English writes that VF Corp (NYSE:VFC), the parent company of The North Face, is facing heightened scrutiny and activist investor pressure due to a 75% stock decline in the last two years.

In “First Citizens Stock Has Taken Off. Its ‘Best Days’ May Be Ahead,” English says that First Citizens Bancshares Inc (NASDAQ:FCNCA) stock has surged this year on the successful integration of Silicon Valley Bank, and analysts expect further gains, although there are potential risks.

In “Altria Stock Selloff Lifts Dividend Yield to Nearly 10%,” Andrew Bary writes that Altria Group Inc‘s (NYSE:MO) stock fell 8% due to an earnings miss and lowered 2023 guidance, leading to a nearly 10% dividend yield, with concerns about a 10% drop in cigarette volume.Read Next: Stellantis And UAW Strike Tentative Agreement, Ending Six-week Labor Strike

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.Photo: Shutterstock

Total
0
Shares
Related Posts
Read More

Scilex Announces Filing Of A New Drug Submission To Health Canada’s Pharmaceutical Drugs Directorate, Bureau Of Cardiology, Allergy And Neurological Sciences For The Approval Of ELYXYB For Acute Treatment Of Migraine With Or Without Aura In Canada

ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The U.S. oral migraine drug market size is

SCLX